These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29721092)

  • 1. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo.
    Tao Z; Liu Y; Yang H; Feng Y; Li H; Shi Q; Li S; Cheng J; Lu X
    Biomacromolecules; 2020 Oct; 21(10):4017-4029. PubMed ID: 32804484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains.
    Siegemund M; Oak P; Hansbauer EM; Allersdorfer A; Utschick K; Winter A; Grasmüller C; Galler G; Mayer JP; Weiche B; Prassler J; Kontermann RE; Rothe C
    Front Pharmacol; 2021; 12():759337. PubMed ID: 34759826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity.
    Yang H; Li H; Yang F; Tao Z; Shi Q; She T; Feng Y; Li Z; Chen J; Zhong Y; Su T; Zeng W; Zhang Y; Wang S; Li L; Long T; Long D; Cheng J; Zhu H; Lu X
    Biomaterials; 2023 Apr; 295():121994. PubMed ID: 36775789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
    Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
    Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
    Kim TH; Jiang HH; Youn YS; Park CW; Lim SM; Jin CH; Tak KK; Lee HS; Lee KC
    J Pharm Sci; 2011 Feb; 100(2):482-91. PubMed ID: 20669330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior serum half life of albumin tagged TNF ligands.
    Müller N; Schneider B; Pfizenmaier K; Wajant H
    Biochem Biophys Res Commun; 2010 Jun; 396(4):793-9. PubMed ID: 20447380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
    Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
    J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.
    Yan J; Wang L; Wang Z; Wang Z; Wang B; Zhu R; Bi J; Wu J; Zhang H; Wu H; Yu B; Kong W; Yu X
    Cell Death Dis; 2016 Jun; 7(6):e2274. PubMed ID: 27336718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a CD70-Specific Fusion Nanobody with IgG Recruiting Capacity for Tumor Killing.
    Liu C; Li J; Hu Q; Xu X; Zhang X
    Int J Nanomedicine; 2023; 18():3325-3338. PubMed ID: 37361386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple hyperthermia-mediated release of TRAIL/SPION nanocomplex from thermosensitive polymeric hydrogels for combination cancer therapy.
    Zhang ZQ; Song SC
    Biomaterials; 2017 Jul; 132():16-27. PubMed ID: 28399459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres.
    Kim H; Jeong D; Kang HE; Lee KC; Na K
    J Pharm Pharmacol; 2013 Jan; 65(1):11-21. PubMed ID: 23215683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 17. Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
    Nie Q; Jia D; Yang H; Feng Y; Fan Q; Shi Q; Wan L; Lu X
    Mol Pharm; 2017 Feb; 14(2):502-512. PubMed ID: 28029256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein.
    Yang X; Xia X; Xia XX; Sun Z; Yan D
    Mol Pharm; 2021 Oct; 18(10):3854-3861. PubMed ID: 34543035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
    Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
    Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A versatile platform for the tumor-targeted delivery of immune checkpoint-blocking immunoglobin G.
    Fan J; Feng Y; Tao Z; Chen J; Yang H; Shi Q; Li Z; She T; Li H; Jin Y; Cheng J; Lu X
    J Control Release; 2021 Dec; 340():243-258. PubMed ID: 34752799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.